Immunogenicity and Therapeutic Efficacy of a Dual-Component Genetic Cancer Vaccine Cotargeting Carcinoembryonic Antigen and HER2/neu in Preclinical Models

摘要: Abstract Several cancer vaccine efforts have been directed to simultaneously cotarget multiple tumor antigens, with the intent achieve broader immune responses and more effective control of growth. Genetic vaccines based on in vivo muscle electro-gene-transfer plasmid DNA (DNA-EGT) adenoviral vectors represent promising modalities elicit powerful against tumor-associated antigens (TAAs) such as carcinoembryonic antigen (CEA) human epidermal growth factor receptor-2 (HER2)/neu. Combinations these immunization (heterologous prime–boost) can induce superior reactions compared single-modality vaccines. We generated a dual component–dual target genetic consisting moiety containing equal amounts two plasmids, one encoding extracellular transmembrane domains HER2 (ECD.TM) other CEA fused B subunit Escherichia coli heat-labile toxin (LTB), an subty...